Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
NCT05637216Phase 2Active, not recruiting
- Sponsor
- Shaw Cancer Center
- Start
- Aug 2023
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of losartan in radiation-induced fibrosis (RIF) (4 arms), sponsored by Shaw Cancer Center. Primary endpoints: Fibrosis of the breast or reconstructed breast at 18 months, Radiographic lung fibrosis at 12 months and 1 more. Started Aug 2023; status: active, not recruiting.
02
Drugs
losartan
03
Conditions
radiation-induced fibrosis (RIF)
Beyond the preview
Go deeper on NCT05637216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05637216.